PMID- 38095214
OWN - NLM
STAT- MEDLINE
DCOM- 20240417
LR  - 20240417
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 116
IP  - 4
DP  - 2024 Apr
TI  - Is ERCP still the elective primary biliary drainage technique in patients with 
      malignant distal biliary obstruction?
PG  - 182-185
LID - 10.17235/reed.2023.10029/2023 [doi]
AB  - Endoscopic retrograde cholangiopancreatography (ERCP) has been established as the 
      first line therapy for the resolution of biliary and pancreatic diseases. The 
      main disadvantage of the procedure is the rate of adverse events, around 10%1. 
      So, despite being a minimally invasive procedure, ERCP has a non-negligible rate 
      of adverse effects (AEs) and secondary mortality.
FAU - Vila, Juan J
AU  - Vila JJ
AUID- ORCID: 0000-0003-1446-3121
AD  - Endoscopy Unit. Gastroenterology Department, Hospital Universitario de Navarra, 
      Espana.
FAU - Jusue Irurita, Vanesa
AU  - Jusue Irurita V
AD  - Endoscopy Unit. Gastroenterology Department, Hospital Universitario de Navarra.
FAU - Rullan Iriarte, Maria
AU  - Rullan Iriarte M
AD  - Endoscopy Unit. Gastroenterology Department, Hospital Universitario de Navarra.
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas
JID - 9007566
SB  - IM
MH  - Humans
MH  - Cholangiopancreatography, Endoscopic Retrograde/adverse effects/methods
MH  - *Cholestasis/diagnostic imaging/etiology/surgery
MH  - Endosonography/adverse effects
MH  - *Bile Duct Neoplasms/complications
MH  - Drainage/adverse effects/methods
EDAT- 2023/12/14 12:42
MHDA- 2024/04/17 06:42
CRDT- 2023/12/14 07:22
PHST- 2024/04/17 06:42 [medline]
PHST- 2023/12/14 12:42 [pubmed]
PHST- 2023/12/14 07:22 [entrez]
AID - 10.17235/reed.2023.10029/2023 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2024 Apr;116(4):182-185. doi: 10.17235/reed.2023.10029/2023.